At a glance
- Originator Fujisawa
- Class Ischaemic heart disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemic heart disorders
Most Recent Events
- 23 Jun 1998 Discontinued for Ischaemic heart disorders
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa